・Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a large Phase 3 trial, prompting the company to end its congenital CMV program. ...
Investing.com -- Leerink analyst warned that Moderna (NASDAQ:MRNA) shares could fall more than 30% if interim results from its Phase 3 CMV vaccine trial, CMVictory gives negative readout. In case of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback